The number of people diagnosed with heart failure is increasing. According to the 2021 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure, approximately 1-2% of adults worldwide have heart failure. Prevalence increases with age, from 1% in those under 55 years to more than 10% in people aged 70 and above. Similarly, the prevalence of atrial fibrillation, an irregular heart rhythm or arrhythmias, is also increasing. According to the 2021 ESC Guidelines, 2-4% of the adult population has atrial fibrillation, with the expectation that this will increase 2-3 times with age.

Bisoprolol and flecainide are two key products used in the treatment of heart failure and atrial fibrillation. Bisopropol is a beta-blocker used to treat high blood pressure. Its benefits are supported by both the ESC Guidelines as well as new evidence uncovered in scientific studies. Flecainide is an an anti-arrhythmic that is used to prevent or treat heart rhythm disorders. The 2021 ESC Guidelines recommend a single administration of flecainide in the diagnosis and treatment of atrial fibrillation.

Additionally, anemia is common in patients with chronic heart failure. Ferrofast, an iron supplement encapsulated in liposomes, is unique in its digestibility and bioavailability, in terms of how quickly it can be absorbed into the body.